Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice

Methodist Research Institute, Clarian Health Partners, Indianapolis, IN 46202, USA.
The British journal of nutrition (Impact Factor: 3.45). 05/2009; 102(7):967-75. DOI: 10.1017/S0007114509345250
Source: PubMed


Muscle wasting or cachexia is caused by accelerated muscle protein breakdown via the ubiquitin-proteasome complex. We investigated the effect of curcumin c3 complex (curcumin c3) on attenuation of muscle proteolysis using in vitro and in vivo models. Our in vitro data indicate that curcumin c3 as low as 0.50 microg/ml was very effective in significantly inhibiting (30 %; P < 0.05) tyrosine release from human skeletal muscle cells, which reached a maximum level of inhibition of 60 % (P < 0.05) at 2.5 microg/ml. Curcumin c3 at 2.5 microg/ml also inhibited chymotrypsin-like 20S proteasome activity in these cells by 25 % (P < 0.05). For in vivo studies, we induced progressive muscle wasting in mice by implanting the MAC16 colon tumour. The in vivo data indicate that low doses of curcumin c3 (100 mg/kg body weight) was able to prevent weight loss in mice bearing MAC16 tumours whereas higher doses of curcumin c3 (250 mg/kg body weight) resulted in approximately 25 % (P < 0.05) weight gain as compared with the placebo-treated animals. Additionally, the effect of curcumin c3 on preventing and/or reversing cachexia was also evident by gains in the weight of the gastrocnemius muscle (30-58 %; P < 0.05) and with the increased size of the muscle fibres (30-65 %; P < 0.05). Furthermore, curcumin inhibited proteasome complex activity and variably reduced expression of muscle-specific ubiquitin ligases: atrogin-1/muscle atrophy F-box (MAFbx) and muscle RING finger 1 (MURF-1). In conclusion, oral curcumin c3 results in the prevention and reversal of weight loss. The data imply that curcumin c3 may be an effective adjuvant therapy against cachexia.

Download full-text


Available from: Rafat Siddiqui
  • Source
    • "its infancy (Steward and Gescher, 2008), and its study as an anti-cancer agent has not yet progressed from animal models (Guo et al., 2012; Lin et al., 2012; Sharma et al., 2011; Yamauchi et al., 2012). On the other hand, curcumin has also shown promising activity in various preclinical models of cancer supportive care (Siddiqui et al., 2009), suggesting that this compound could have a significant impact on therapeutic compliance, reduction of adverse events, and quality of life in cancer patients. One major problem with curcumin, especially marked in a supportive care context, is its dismally low oral bioavailability , especially from non-dietary pharmaceutical matrixes, with the need to administer mega-dosages (up to 8 grams) of this compound to patients with often already altered taste perception, difficulties to swallow, and intestinal disturbances (Dhillon et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A proprietary lecithin delivery system of curcumin (Meriva) was evaluated in a controlled study to assess its efficacy in alleviating the side effects of cancer chemo- and radiotherapy in 160 patients undergoing these treatments. In both cases, a semi-quantitative evaluation of the side effects was carried out using a visual analogue scale, assessing also the plasma free radical status in all patients. Results showed that lecithinized curcumin might alleviate the burden of side effects associated to chemo- and radiotherapy, suggesting that the anecdotal use of various preparations of curcumin as a supportive agent for cancer treatment is well worth a systematic investigation in larger scale clinical trials. The capacity of curcumin to upregulate anti-oxidative responses and downregulate inflammatory pathways could explain its beneficial effect in tempering the prolonged and systemic oxidative and inflammatory effects of cancer treatment, and the beneficial effects observed in the plasma oxidative status in all patients of the treatment group support this view. © 2013 The Authors. Phytotherapy Research published by John Wiley & Sons, Ltd.
    Full-text · Article · Mar 2014 · Phytotherapy Research
  • Source
    • "Each set of 18 rats was further divided into three sub-groups: Control, acetylsalicylic acid (ASA), and curcumin (Cur). Animals in the control group were injected with 0.9% saline, the second group of animals were injected with acetylsalicylic acid (10mg/kg), and the third group with curcumin (100mg/kg) intra-peritoneally [25] and the following tests were performed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study was designed to investigate the gastroprotective, analgesic, and antipyretic effects of curcumin (Cur), the major constituent of turmeric. Acetylsalicylic acid (ASA) was used in this study as a standard drug for comparison. The analgesic activity was measured using the Hot-Plate Test. The antipyretic and antiulcer effects were assessed using yeast-induced pyrexia and gastric ulceration, respectively. Curcumin (100 mg/kg) injected intra-peritoneally 1 hr prior to the Hot-Plate Test showed significant analgesic activity expressed by both parameters: an increase in latency time and a reduction in paw licking as compared to the controls. In the animal model of pyrexia, curcumin (100 mg/kg injected intra-peritoneally) exhibited a significant reduction in the rectal temperature after 1 hr, 2 hrs, 4 hrs, and 5 hrs of treatment, indicating the antipyretic effect of curcumin. Rats with orally administered curcumin (200 mg/kg) did not show any lesions on the inner lining of the stomach after a 16 hr fast, indicating the gastroprotective effects of curcumin as compared to saline- and acetylsalicylic acid-administered rats. The significantly low ulcer index in curcumin-treated rats following starvation highlights the gastroprotective characteristics of curcumin.
    Full-text · Article · Jun 2013 · Scientia Pharmaceutica
  • [Show abstract] [Hide abstract]
    ABSTRACT: Negative corona discharge from a novel linear metal point array structure has been investigated. The inherent advantage of using such a structure is that its rigidity eliminates vibration and sagging problems experienced by conventional wire corona emitters. More importantly, it is found that longitudinal current emission more uniform than that from wire emitters can be obtained by sufficiently reducing the point spacing of the point array. This current uniformity is stable with time. The current emission by the point array is proportional to V ( V - V <sub>0</sub>), where V <sub>0</sub> is the threshold voltage for corona discharge. The lateral current distribution can be described by Warburg's law. Observation of corona glow in the dark indicates that discharge occurs at each point for large point spacings. When the point spacing is reduced to less than 2 mm, corona glow occurs generally at alternate points at intermediate field strengths and at every point when the field strength is raised further. A qualitative explanation of the different corona glow situations is given
    No preview · Conference Paper · Nov 1993
Show more